3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
144
Neoplasm Metastasis
16
Neoplasms
8
Advanced Breast Cancer
8
Ovarian Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Breast Cancer Metastatic
5
Prostatic Neoplasms
4
Endometrial Neoplasms
4
Recurrence
3
Hereditary Sensory and Autonomic Neuropathies
3
Lung Neoplasms
2
Hyperglycemia
2
Exanthema
2
Estrogen Receptor-positive Breast Cancer
2
Colorectal Neoplasms
2
Carcinoma, Lobular
2
Breast Neoplasms, Male
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sex Cord-Gonadal Stromal Tumors
1
Sarcoma, Endometrial Stromal
1
Salivary Gland Neoplasms
1
Recurrent Uterine Corpus Carcinoma
1
Neoplastic Cells, Circulating
1
Interventions
Octreotide
2
telotristat ethyl
1
isatuximab
1
ceterizine hydrochloride
1
capivasertib
1
cabazitaxel
1
XRP6258
1
Prednisone
1
Loperamide
1
Leucovorin
1
Lapatinib
1
Irinotecan
1
Injections
1
Granulocyte Colony-Stimulating Factor
1
Fulvestrant
1
Fluorouracil
1
Filgrastim
1
Drugs, Investigational
1
Cyclophosphamide
1
Colesevelam Hydrochloride
1
Cell- and Tissue-Based Therapy
1
Capecitabine
1
Calcium Aluminosilicate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Diarrhea
×
Fulvestrant
×
Clear all
NCT07426822
2026-02-24
SAFE-CAP
Yale University
Phase 2
Not yet recruiting
108 enrolled